Developer docs
API playgroundTry for free, no card

Search company profiles

Basic Pharma

Full company profile

uuid0009ysc

Namestring
Basic Pharma
Legal namestring
Basic Pharma
Websiteurl
basicpharma.nl
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Basic Pharma is a Netherlands-based, privately held pharmaceutical Contract Development and Manufacturing Organization (CDMO) founded in 2003 and headquartered in Geleen. The company operates a single GMP-certified facility offering end-to-end pharmaceutical services spanning formulation development, API manufacturing, analytical testing, regulatory affairs, pharmacovigilance, and commercial production across multiple dosage forms including liquids, semi-solids, nasal sprays, prefilled syringes, and vials. Basic Pharma holds GMP certification from Dutch authorities and ISO 13485:2016 certification, with experienced Qualified Persons enabling QP release for European market supply.

The company operates three integrated business lines. The core CDMO/CMO service line delivers project-based contract manufacturing for pharmaceutical companies from early clinical phase through commercialization. A generic medicinal products division develops formulations in-house and licenses the resulting dossiers (in e-CTD format) to partners across multiple territories, creating a licensing and royalty revenue stream. The Basic Pharma Biotech sub-brand extends CDMO capabilities into biologicals, offering recombinant protein expression services using validated microbial platforms (E. coli, Pichia pastoris, Hansenula polymorpha yeast) with bioreactor capacity from 0.5L to 50L, alongside a catalog of research-grade recombinant proteins (rHSA, Histone H3, sfGFP, TEV Protease, MBP) sold directly to universities, laboratories, and biotech companies worldwide.

Revenue is generated through three channels: professional services fees for CDMO contracts, licensing royalties from generic product partnerships, and direct unit-based sales of catalog biotech products priced between €95 and €1,245. Go-to-market is direct sales-led with engagement via the company website, industry events, and strategic partnerships — notably with Maastricht University for Histone H3 co-development and ARTES Biotechnology for rHSA manufacturing. Customer segments include pharmaceutical companies, biotech companies, academic and research institutions, and generic product licensing partners. The company maintains worldwide delivery capabilities for biotech products and serves pharmaceutical clients globally through direct engagement.

Short descriptiontext

Basic Pharma is a Netherlands-based pharmaceutical CDMO offering GMP-certified development, manufacturing, and regulatory services for pharmaceutical and biotech companies. It also licenses a proprietary generic product portfolio and operates a biotech division producing research-grade recombinant proteins for global academic and commercial customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersGeleen, Netherlands
HQ citystring
Geleen
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical CDMO services, contract manufacturing, recombinant protein expression, generic drug licensing, GMP pharmaceutical manufacturing
Industry7 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code4 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical and Medicine Manufacturing3254
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical CDMO Services
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1CDMO/Contract Manufacturing Services
TypeProfessional Services
Description

Full-service contract development and manufacturing services for pharmaceutical products, including formulation development, analytical testing, regulatory support, and commercial manufacturing. Revenue generated through project-based contracts with pharmaceutical and biotech companies.

basicpharma.nl
2Generic Product Licensing
TypeLicensing Royalties
Description

Development and out-licensing of generic medicinal products. Basic Pharma develops products in-house and licenses them to partners in multiple territories. Also offers in-licensing and co-development arrangements.

basicpharma.nl
3Biotech Products (Recombinant Proteins)
TypeOne Time License
Description

Sale of research-grade recombinant proteins including Human Serum Albumin, Histone H3, sfGFP, TEV Protease, and MBP. Products are sold directly to universities, laboratories, and biotech companies worldwide with batch-specific CoA documentation.

basicpharma.nl
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Pricing details5 tiers
1Human Serum Albumin (rHSA) - Lyophilized recombinant protein from Hansenula polymorpha yeast
ModelUnit PricingBilling cadencePay-as-you-go
Notes

50 µg: €95 | 500 µg: €245 | 1000 µg: €395. Batch-specific Certificate of Analysis included.

basicpharma.nl
2Histone H3 - Recombinant from E. coli, >95% purity
ModelUnit PricingBilling cadencePay-as-you-go
Notes

100 µg: €249 | 1000 µg: €1245

basicpharma.nl
3sfGFP - Superfolder GFP recombinant from E. coli, >95% purity
ModelUnit PricingBilling cadencePay-as-you-go
Notes

100 µg: €229 | 1000 µg: €1145

basicpharma.nl
4TEV Protease - Recombinant cysteine protease
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Pricing upon request; lyophilized format with stability at -20°C for at least 6 months

basicpharma.nl
5Maltose Binding Protein (MBP) - Recombinant from E. coli, >95% purity
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Packaging sizes upon request; lyophilized from buffer (50 mM Tris; 300 mM NaCl; pH 7.2)

basicpharma.nl
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Basic Pharma Biotech
Description

Biotech division focused on recombinant protein expression, production, and purification services for the pharmaceutical and biotechnology industries.

basicpharma.nl
Core offering1 text field

Basic Pharma is a full-service pharmaceutical CDMO providing contract development, GMP-compliant manufacturing, analytical laboratory testing, and regulatory consultancy for pharmaceutical companies from lab scale to early clinical phase and beyond. The company maintains an in-house generic medicinal product portfolio available for out-licensing and operates a biotech division that produces research-grade and GMP-grade recombinant proteins via microbial expression systems (E. coli, Pichia pastoris, Hansenula polymorpha) for biotech companies, universities, and laboratories worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Stable product development with climate chambers maintaining temperature and humidity control for ICH stability studies
+1 more record
Product and service6 records
1CDMO/Contract Manufacturing Services
CategoryContract pharmaceutical manufacturing
Description

Full-service contract development and manufacturing organization (CDMO) services covering formulation development, GMP-compliant manufacturing, IMP manufacturing, aseptic fill-finish with isolators for cytotoxic compounds, lyophilization, packaging with FMD serialization, and compounding from lab scale through early clinical phase to commercial production for pharmaceutical and biotech clients.

2Laboratory and Analytical Testing Services
CategoryPharmaceutical analytical and laboratory services
Description

ICH-compliant analytical testing services including HPLC (UV, DAD, IR, fluorescence detection), microbiological testing, stability studies across approximately 100 m² of controlled climate chambers, and method development/validation according to Ph. Eur. or USP methods for pharmaceutical clients.

3Regulatory and Scientific Consultancy Services
CategoryPharmaceutical regulatory and scientific consulting
Description

Expert consultancy in regulatory affairs, quality assurance, pharmacovigilance, and clinical research, supporting pharmaceutical clients in navigating market authorization and product development pathways.

4In-house Generic Medicinal Product Portfolio (Out-licensing)
CategoryGeneric pharmaceutical licensing
Description

Portfolio of in-house developed generic prescription and OTC medicinal products, available for out-licensing to partners across multiple territories, with product dossiers in e-CTD format and supported by in-licensing and co-development arrangements.

5Recombinant Protein Catalog Products
CategoryRecombinant protein products
Description

Catalog of research-grade recombinant proteins including Human Serum Albumin (rHSA, Hansenula polymorpha), Histone H3 (E. coli), sfGFP (E. coli), TEV Protease, and Maltose Binding Protein (MBP), each supplied lyophilized with batch-specific Certificates of Analysis to universities, laboratories, and biotech companies worldwide.

6Custom Recombinant Protein Expression and Bioprocess Services
CategoryContract recombinant protein development and production
Description

Bespoke contract services for recombinant protein expression and bioprocess development using BSL-2 microbial expression systems in E. coli, Pichia pastoris, and Hansenula polymorpha, with bioreactor capacity ranging from 0.5L to 50L, bioprocess homogenization up to 1200 bars, chromatography at R&D and pilot scale, tangential flow filtration, and lyophilization for biotech clients from R&D to preclinical and pilot scale.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration for the development and manufacturing of recombinant Histone H3. Combines expertise of an academic research institute with an industrial company in protein engineering. The Histone H3 product is produced using Basic Pharma's E. coli expression platform developed in partnership.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration for the development and manufacturing of recombinant Human Serum Albumin (rHSA). ARTES Biotechnology contributes expertise in yeast-based protein expression using Hansenula polymorpha, while Basic Pharma provides GMP manufacturing capabilities and commercial distribution.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers3 records
TypeOthers
2Recipharm
TypeDirect peer
Description

European CDMO providing development, manufacturing, and analytical services across multiple dosage forms including sterile injectables and inhalation products. Comparable to Basic Pharma in its full-service pharma CDMO offering and European customer base.

TypeDirect peer
Description

European mid-sized CDMO offering solid, semi-solid, and liquid dosage form development and manufacturing including softgel and sterile capabilities. Directly comparable to Basic Pharma in integrated small-molecule CDMO services for pharma and biotech customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Basic Pharma

Pharmaceutical CDMO Servicesbasicpharma.nl

Basic Pharma is a Netherlands-based pharmaceutical CDMO offering GMP-certified development, manufacturing, and regulatory services for pharmaceutical and biotech companies. It also licenses a proprietary generic product portfolio and operates a biotech division producing research-grade recombinant proteins for global academic and commercial customers.

What Basic Pharma does

Basic Pharma is a Netherlands-based, privately held pharmaceutical Contract Development and Manufacturing Organization (CDMO) founded in 2003 and headquartered in Geleen. The company operates a single GMP-certified facility offering end-to-end pharmaceutical services spanning formulation development, API manufacturing, analytical testing, regulatory affairs, pharmacovigilance, and commercial production across multiple dosage forms including liquids, semi-solids, nasal sprays, prefilled syringes, and vials. Basic Pharma holds GMP certification from Dutch authorities and ISO 13485:2016 certification, with experienced Qualified Persons enabling QP release for European market supply.

The company operates three integrated business lines. The core CDMO/CMO service line delivers project-based contract manufacturing for pharmaceutical companies from early clinical phase through commercialization. A generic medicinal products division develops formulations in-house and licenses the resulting dossiers (in e-CTD format) to partners across multiple territories, creating a licensing and royalty revenue stream. The Basic Pharma Biotech sub-brand extends CDMO capabilities into biologicals, offering recombinant protein expression services using validated microbial platforms (E. coli, Pichia pastoris, Hansenula polymorpha yeast) with bioreactor capacity from 0.5L to 50L, alongside a catalog of research-grade recombinant proteins (rHSA, Histone H3, sfGFP, TEV Protease, MBP) sold directly to universities, laboratories, and biotech companies worldwide.

Revenue is generated through three channels: professional services fees for CDMO contracts, licensing royalties from generic product partnerships, and direct unit-based sales of catalog biotech products priced between €95 and €1,245. Go-to-market is direct sales-led with engagement via the company website, industry events, and strategic partnerships — notably with Maastricht University for Histone H3 co-development and ARTES Biotechnology for rHSA manufacturing. Customer segments include pharmaceutical companies, biotech companies, academic and research institutions, and generic product licensing partners. The company maintains worldwide delivery capabilities for biotech products and serves pharmaceutical clients globally through direct engagement.

Basic Pharma firmographics

Firmographics
Name
Basic Pharma
Legal name
Basic Pharma
Website
https://basicpharma.nl
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
101–250 employees
Short description
Basic Pharma is a Netherlands-based pharmaceutical CDMO offering GMP-certified development, manufacturing, and regulatory services for pharmaceutical and biotech companies. It also licenses a proprietary generic product portfolio and operates a biotech division producing research-grade recombinant proteins for global academic and commercial customers.
Ownership category
akta.pro rank

Basic Pharma industry classification

Industry
Product category
Pharmaceutical CDMO Services
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Pharmaceutical CDMO services
  • Contract manufacturing
  • Recombinant protein expression
  • Generic drug licensing
  • GMP pharmaceutical manufacturing

Where Basic Pharma is headquartered

Location

Headquarters

HQ city
Geleen
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

Basic Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. CDMO/Contract Manufacturing Services: Full-service contract development and manufacturing services for pharmaceutical products, including formulation development, analytical testing, regulatory support, and commercial manufacturing. Revenue generated through project-based contracts with pharmaceutical and biotech companies.
  2. Generic Product Licensing: Development and out-licensing of generic medicinal products. Basic Pharma develops products in-house and licenses them to partners in multiple territories. Also offers in-licensing and co-development arrangements.
  3. Biotech Products (Recombinant Proteins): Sale of research-grade recombinant proteins including Human Serum Albumin, Histone H3, sfGFP, TEV Protease, and MBP. Products are sold directly to universities, laboratories, and biotech companies worldwide with batch-specific CoA documentation.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goHuman Serum Albumin (rHSA) - Lyophilized recombinant protein from Hansenula polymorpha yeast
Unit PricingPay-as-you-goHistone H3 - Recombinant from E. coli, >95% purity
Unit PricingPay-as-you-gosfGFP - Superfolder GFP recombinant from E. coli, >95% purity
Unit PricingPay-as-you-goTEV Protease - Recombinant cysteine protease
Unit PricingPay-as-you-goMaltose Binding Protein (MBP) - Recombinant from E. coli, >95% purity

Go-to-market motion3 records

Distribution channels2 records

Marketing channels4 records

Basic Pharma product offering

Product offering

Core offering

Basic Pharma is a full-service pharmaceutical CDMO providing contract development, GMP-compliant manufacturing, analytical laboratory testing, and regulatory consultancy for pharmaceutical companies from lab scale to early clinical phase and beyond. The company maintains an in-house generic medicinal product portfolio available for out-licensing and operates a biotech division that produces research-grade and GMP-grade recombinant proteins via microbial expression systems (E. coli, Pichia pastoris, Hansenula polymorpha) for biotech companies, universities, and laboratories worldwide.

Differentiator

Problem solved

Functional benefit

Brands

  • Basic Pharma Biotech: Biotech division focused on recombinant protein expression, production, and purification services for the pharmaceutical and biotechnology industries.

Products and services

  • CDMO/Contract Manufacturing Services Full-service contract development and manufacturing organization (CDMO) services covering formulation development, GMP-compliant manufacturing, IMP manufacturing, aseptic fill-finish with isolators for cytotoxic compounds, lyophilization, packaging with FMD serialization, and compounding from lab scale through early clinical phase to commercial production for pharmaceutical and biotech clients.
  • Laboratory and Analytical Testing Services ICH-compliant analytical testing services including HPLC (UV, DAD, IR, fluorescence detection), microbiological testing, stability studies across approximately 100 m² of controlled climate chambers, and method development/validation according to Ph. Eur. or USP methods for pharmaceutical clients.
  • Regulatory and Scientific Consultancy Services Expert consultancy in regulatory affairs, quality assurance, pharmacovigilance, and clinical research, supporting pharmaceutical clients in navigating market authorization and product development pathways.
  • In-house Generic Medicinal Product Portfolio (Out-licensing) Portfolio of in-house developed generic prescription and OTC medicinal products, available for out-licensing to partners across multiple territories, with product dossiers in e-CTD format and supported by in-licensing and co-development arrangements.
  • Recombinant Protein Catalog Products Catalog of research-grade recombinant proteins including Human Serum Albumin (rHSA, Hansenula polymorpha), Histone H3 (E. coli), sfGFP (E. coli), TEV Protease, and Maltose Binding Protein (MBP), each supplied lyophilized with batch-specific Certificates of Analysis to universities, laboratories, and biotech companies worldwide.
  • Custom Recombinant Protein Expression and Bioprocess Services Bespoke contract services for recombinant protein expression and bioprocess development using BSL-2 microbial expression systems in E. coli, Pichia pastoris, and Hansenula polymorpha, with bioreactor capacity ranging from 0.5L to 50L, bioprocess homogenization up to 1200 bars, chromatography at R&D and pilot scale, tangential flow filtration, and lyophilization for biotech clients from R&D to preclinical and pilot scale.

Quantifiable outcome

  • Stable product development with climate chambers maintaining temperature and humidity control for ICH stability studies
  • +1 more outcomes

Companies that use Basic Pharma

Customer profile

Segments4 records

Ideal customer profiles4 records

Basic Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Basic Pharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Maastricht UniversitycoreStrategic or Co-development PartnerCollaboration for the development and manufacturing of recombinant Histone H3. Combines expertise of an academic research institute with an industrial company in protein engineering. The Histone H3 product is produced using Basic Pharma's E. coli expression platform developed in partnership.
  • ARTES BiotechnologycoreStrategic or Co-development PartnerCollaboration for the development and manufacturing of recombinant Human Serum Albumin (rHSA). ARTES Biotechnology contributes expertise in yeast-based protein expression using Hansenula polymorpha, while Basic Pharma provides GMP manufacturing capabilities and commercial distribution.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Basic Pharma competitors and assessment

Company assessment

Others

Direct peers

  • Recipharm: European CDMO providing development, manufacturing, and analytical services across multiple dosage forms including sterile injectables and inhalation products. Comparable to Basic Pharma in its full-service pharma CDMO offering and European customer base.
  • Aenova Group: European mid-sized CDMO offering solid, semi-solid, and liquid dosage form development and manufacturing including softgel and sterile capabilities. Directly comparable to Basic Pharma in integrated small-molecule CDMO services for pharma and biotech customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Basic Pharma social profiles

Digital presence

Basic Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Basic Pharma leadership team

Management profile

Number of profiles

Profiles3 records

Basic Pharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Basic Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Basic Pharma

What does Basic Pharma do?

Basic Pharma is a full-service pharmaceutical CDMO providing contract development, GMP-compliant manufacturing, analytical laboratory testing, and regulatory consultancy for pharmaceutical companies from lab scale to early clinical phase and beyond. The company maintains an in-house generic medicinal product portfolio available for out-licensing and operates a biotech division that produces research-grade and GMP-grade recombinant proteins via microbial expression systems (E. coli, Pichia pastoris, Hansenula polymorpha) for biotech companies, universities, and laboratories worldwide.

Is Basic Pharma a public or private company?

Basic Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Basic Pharma founded?

Basic Pharma was founded in 2003. It employs 101 to 250 people.

Where is Basic Pharma based?

Basic Pharma is headquartered in Geleen, Netherlands, in the Europe region.

How does Basic Pharma make money?

Three revenue lines are on record. CDMO/Contract Manufacturing Services are the primary driver. The others are generic Product Licensing and biotech Products (Recombinant Proteins).

Who are Basic Pharma's main competitors?

Hovione is listed as an others. Direct peers are Recipharm and Aenova Group.

Does Basic Pharma have an API?

No public API is recorded for Basic Pharma.

What industry is Basic Pharma in?

Basic Pharma's product category is Pharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals